EUVIMEDEUVIMED entdecken
Crossref

Feasibility of combining high-dose-rate prostate brachytherapy with dose intensification to the MRI dominant lesion followed by real-time adaptive MR-guided pelvic radiotherapy for high-risk prostate cancer

Gil'ad N Cohen, Jason Gurewitz, Jennifer Johnson, Jeffrey Cooney, Yuhao Shi, Harry Adler, Matthew Long, David J Byun, Michael J Zelefsky

Brachytherapy · 2026

DOI: 10.1016/j.brachy.2025.10.013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brachytherapy, 2026. Verfasst von Gil'ad N Cohen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, NYU Grossman School of Medicine, New York, NY. Electronic address: gil'ad.cohen@nyulangone.org. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Brachytherapy, Radiotherapy, Image-Guided, Radiosurgery. Die Arbeit nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Optimizing radiotherapy delivery for higher-risk prostate cancer often requires dose escalation while minimizing dose to surrounding normal tissues. We report on the feasibility of combining high-dose-rate (HDR) brachytherapy with dose intensification to the dominant intra-prostatic lesion (DIL) followed by magnetic resonance-guided stereotactic body radiotherapy (MRgSBRT). METHODS AND MATERIALS: Eighty-eight patients were treated with a single fraction of 15-Gy HDR brachytherapy boost followed by MRgSBRT to prostate, or prostate and pelvic lymph nodes, to a dose of 25 Gy in five fractions. The DIL noted on multi-parametric MR imaging was defined as a PIRADS-4/-5 lesion with an associated diffusion-weighted abnormality(s), and was intraoperatively boosted during brachytherapy to 120% of the prescription dose. Dosimetric objectives included D99% >120% to the DIL, D1%

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsBrachytherapyRadiotherapy, Image-GuidedRadiosurgeryHumansMaleFeasibility StudiesAgedRadiotherapy DosageMiddle AgedAged, 80 and overMagnetic Resonance ImagingMagnetic Resonance Imaging, InterventionalPelvis

Stichwörter der Autor:innen

DIL boostHDRMRgSBRTProstate

Autor:innen und Institutionen

  • Department of Radiation Oncology, NYU Grossman School of Medicine, New York, NY. Electronic address: gil'ad.cohen@nyulangone.org.
  • Department of Radiation Oncology, NYU Grossman School of Medicine, New York, NY.

Zitieren

APA

Cohen, G. N., Gurewitz, J., Johnson, J., Cooney, J., Shi, Y., Adler, H., Long, M., Byun, D. J., & Zelefsky, M. J. (2026). Feasibility of combining high-dose-rate prostate brachytherapy with dose intensification to the MRI dominant lesion followed by real-time adaptive MR-guided pelvic radiotherapy for high-risk prostate cancer. Brachytherapy. https://doi.org/10.1016/j.brachy.2025.10.013

Vancouver

Cohen GN, Gurewitz J, Johnson J, Cooney J, Shi Y, Adler H, et al. Feasibility of combining high-dose-rate prostate brachytherapy with dose intensification to the MRI dominant lesion followed by real-time adaptive MR-guided pelvic radiotherapy for high-risk prostate cancer. Brachytherapy. 2026. doi:10.1016/j.brachy.2025.10.013

BibTeX
@article{Cohen2026,
  author = {Cohen, Gil'ad N and Gurewitz, Jason and Johnson, Jennifer and Cooney, Jeffrey and Shi, Yuhao and Adler, Harry and Long, Matthew and Byun, David J and Zelefsky, Michael J},
  title = {Feasibility of combining high-dose-rate prostate brachytherapy with dose intensification to the MRI dominant lesion followed by real-time adaptive MR-guided pelvic radiotherapy for high-risk prostate cancer},
  journal = {Brachytherapy},
  year = {2026},
  doi = {10.1016/j.brachy.2025.10.013}
}
Kostenlos starten →